Anti-CD1d treatment decreases the percentage of pulmonary lymphocytes expressing CXCR3 and reduces lung homogenate levels of IFN-γ and IFN-γ–inducible chemokines. (A) Representative flow cytometry plots of CXCR3 expression on pulmonary lymphocytes from NY1DD isotype-treated, NY1DD 1 day after anti-CD1d treatment, and NY1DD 5 days after anti-CD1d treatment. (B) Pulmonary lymphocytes from NY1DD mice express decreased CXCR3 when harvested 1 day, but not 5 days, after anti-CD1d. (C-D) Pulmonary tissues harvested from NY1DD animals have reduced levels of IFN-γ and IFN-γ–inducible chemokines when harvested 1 day, but not 5 days, after anti-CD1d. Data were analyzed by one-way ANOVA with Neuman-Keuls posttesting (*P < .05).